blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3231440

EP3231440 - MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  07.05.2021
Database last updated on 14.09.2024
FormerExamination is in progress
Status updated on  21.08.2020
FormerRequest for examination was made
Status updated on  27.04.2018
FormerThe application has been published
Status updated on  15.09.2017
Most recent event   Tooltip07.05.2021Application deemed to be withdrawnpublished on 09.06.2021  [2021/23]
Applicant(s)For all designated states
CSL Behring GmbH
Emil-von-Behring-Strasse 76
35041 Marburg / DE
[2017/42]
Inventor(s)01 / SCHULTE, Stefan
Bauerbacher Strasse 46
35043 Marburg / DE
02 / WEIMER, Thomas
Richard-Wagner-Strasse 8
35075 Gladenbach / DE
03 / METZNER, Hubert
Im Boden 6
35041 Marburg / DE
 [2017/42]
Representative(s)Ludwig, Holger, et al
CSL Behring AG
Wankdorfstrasse 10
3014 Bern / CH
[N/P]
Former [2017/42]Ludwig, Holger, et al
CSL Behring GmbH
Emil-von-Behring-Straße 76
35041 Marburg / DE
Application number, filing date17167481.521.12.2007
[2017/42]
Priority number, dateEP2006002674722.12.2006         Original published format: EP 06026747
US20070879334P09.01.2007         Original published format: US 879334 P
[2017/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3231440
Date:18.10.2017
Language:EN
[2017/42]
Search report(s)(Supplementary) European search report - dispatched on:EP11.09.2017
ClassificationIPC:A61K38/37, A61K38/38, C07K14/755, C07K14/76, C12N15/09, C07K14/745, C07K14/765, C07K16/18
[2017/42]
CPC:
C07K14/755 (EP,US); A61P7/04 (EP); C07K14/745 (EP,US);
C07K14/765 (US); C07K16/18 (US); C07K2319/31 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2018/22]
Former [2017/42]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:VERÄNDERTE KOAGULATIONSFAKTOREN MIT VERLÄNGERTER IN-VIVO-HALBWERTZEIT[2017/42]
English:MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE[2017/42]
French:FACTEURS DE COAGULATION MODIFIÉS AVEC UNE DEMI-VIE IN VIVO PROLONGÉE[2017/42]
Examination procedure21.04.2017Date on which the examining division has become responsible
18.04.2018Amendment by applicant (claims and/or description)
18.04.2018Examination requested  [2018/22]
24.08.2020Despatch of a communication from the examining division (Time limit: M04)
12.01.2021Application deemed to be withdrawn, date of legal effect  [2021/23]
03.02.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2021/23]
Parent application(s)   TooltipEP07857067.8  / EP2097096
Fees paidRenewal fee
21.08.2017Renewal fee patent year 03
21.08.2017Renewal fee patent year 04
21.08.2017Renewal fee patent year 05
21.08.2017Renewal fee patent year 06
21.08.2017Renewal fee patent year 07
21.08.2017Renewal fee patent year 08
21.08.2017Renewal fee patent year 09
21.08.2017Renewal fee patent year 10
02.01.2018Renewal fee patent year 11
02.01.2019Renewal fee patent year 12
02.01.2020Renewal fee patent year 13
Penalty fee
Additional fee for renewal fee
31.12.202014   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[IY]WO2006108590  (ZLB BEHRING GMBH [DE], et al) [I] 1-21 * Th whole document, but see in particular page 5, last paragraph; page 6, lines 1-6; pages 23,24; claims 1-19 * [Y] 1-21;
 [Y]WO2006027111  (ZLB BEHRING GMBH [DE], et al) [Y] 1-21 * the whole document *;
 [Y]WO2005111074  (ZLB BEHRING GMBH [DE], et al) [Y] 1-21 * the whole document *;
 [Y]WO2004082640  (NEW CENTURY PHARMACEUTICALS [US], et al) [Y] 1-21 * the whole document *;
 [Y]EP1444986  (AVENTIS BEHRING GMBH [DE]) [Y] 1-21 * the whole document *;
 [Y]US5364771  (LOLLAR JOHN S [US], et al) [Y] 1-21 * the whole document *;
 [Y]WO0168109  (UNIV EMORY [US]) [Y] 1-21 * the whole document *;
 [Y]WO0071714  (AMERICAN NAT RED CROSS [US], et al) [Y] 1-21 * the whole document *;
 [Y]WO0101749  (GENENTECH INC [US]) [Y] 1-21 * the whole document *;
 [YD]WO2004101740  (SYNTONIX PHARMACEUTICALS INC [US], et al) [YD] 1-21 * the whole document *;
 [YD]WO0179271  (PRINCIPIA PHARMACEUTICAL CORP [US], et al) [YD] 1-21 * the whole document *;
 [YD]WO2005024044  (GTC BIOTHERAPEUTICS INC [US], et al) [YD] 1-21 * the whole document *;
 [YP]EP1867660  (CSL BEHRING GMBH [DE]) [YP] 1-21 * the whole document *;
 [YP]EP1816201  (CSL BEHRING GMBH [DE]) [YP] 1-21 * See in particular paragraph [0054] and Table 3 *
 [Y]  - SHEFFIELD W P ET AL, "Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits", BRITISH JOURNAL OF HAEMATOLOGY, OXFORD, GB, (200408), vol. 126, no. 4, ISSN 0007-1048, pages 565 - 573, XP002395198 [Y] 1-21 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1365-2141.2004.05106.x
 [Y]  - LIN YI ET AL, "Use of blood outgrowth endothelial cells for gene therapy for hemophilia A", BLOOD, (20020115), vol. 99, no. 2, ISSN 0006-4971, pages 457 - 462, XP002430423 [Y] 1-21 * the whole document *

DOI:   http://dx.doi.org/10.1182/blood.V99.2.457
 [YD]  - PIPE S W ET AL, "Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, (199710), vol. 94, ISSN 0027-8424, pages 11851 - 11856, XP002969281 [YD] 1-21 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.94.22.11851
 [Y]  - PITTMAN D D ET AL, "BIOCHEMICAL, IMMUNOLOGICAL, AND IN VIVO FUNCTIONAL CHARACTERIZATIONOF B-DOMAIN-DELETED FACTOR VIII", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, (19930601), vol. 81, no. 11, ISSN 0006-4971, pages 2925 - 2935, XP000676711 [Y] 1-21 * the whole document *
by applicantWO03093313
 WO02060951
 WO9415625
 WO9711957
 US4970300
 WO9955306
 WO9703193
 WO9740145
 WO03087355
 WO02072023
 WO02103024
 WO2006108590
 WO0179271
 WO2005024044
 WO2004101740
 US2004087778
 WO2005001025
 WO2006000448
 WO2005063808
 WO03076567
 WO2005000892
 US6403077
 WO2004005347
    - WOOD ET AL., NATURE, (1984), vol. 312, pages 330 - 336
    - VEHAR ET AL., NATURE, (1984), vol. 312, pages 337 - 342
    - SAENKO ET AL., VOX SANG., (2002), vol. 83, pages 89 - 96
    - FAY ET AL., J. BIOL. CHEM., (1991), vol. 266, page 8957
    - FAY; SMUDZIN, J. BIOL. CHEM., (1992), vol. 267, pages 13246 - 50
    - PIPE; KAUFMAN, PNAS, (1997), vol. 94, pages 11851 - 11856
    - GALE ET AL., PROTEIN SCIENCE, (2002), vol. 11, pages 2091 - 2101
    - GALE ET AL., J. THROMB. HAEMOST., (2003), vol. 1, pages 1966 - 1971
    - ALEDORT, J THROMB HAEMOST, (2004), vol. 2, pages 1700 - 1708
    - BEATTIE; DUGAICZYK, GENE, (1982), vol. 20, pages 415 - 422
    - LICHENSTEIN ET AL., J. BIOL. CHEM., (1994), vol. 269, pages 18149 - 18154
    - COOKE; DAVID, J. CLIN. INVEST., (1985), vol. 76, pages 2420 - 2424
    - DUMONT JA ET AL., BIODRUGS, (2006), vol. 20, pages 151 - 160
    - AMANO, THROMB. HAEMOST., (1998), vol. 79, pages 557 - 563
    - SWAROOP ET AL., JBC, (1997), vol. 272, pages 24121 - 24124
    - LOLLAR, THROMB. HAEMOST., (1999), vol. 82, pages 505 - 508
    - OH ET AL., EXP. MOL. MED., (1999), vol. 31, pages 95 - 100
    - ANANYEVA ET AL., TCM, (2001), vol. 11, pages 251 - 257
    - GALE ET AL., J. THROMB. HEMOST., (2006), vol. 4, pages 1315 - 1322
    - MIAO ET AL., BLOOD, (2004), vol. 103, pages 3412 - 3419
    - WAKABAYASHI ET AL., BIOCHEMISTRY, (2005), vol. 44, pages 10298 - 304
    - PIPE, SEM. THROMB. HEMOST., (2004), vol. 30, pages 227 - 237
    - S. ROSEN, SCAND J HAEMATOL, (1984), vol. 33, pages 139 - 145
    - PITTMAN ET AL., BLOOD, (1992), vol. 81, pages 2925 - 2935
    - NAKAYAMA, BIOCHEM. J., (1997), vol. 327, pages 625 - 635
    - COLLINS ET AL., PROC NATL. ACAD. SCI. USA, (1987), vol. 84, pages 4393 - 4397
    - FEDERICI AB ET AL., HAEMATOLOGICA, (2004), vol. 89, pages 77 - 85
    - SUCKER ET AL., CLIN APPL THROMB HEMOST., (2006), vol. 12, pages 305 - 310
    - KALLAS; TALPSEP, ANNALS OF HEMATOLOGY, (2001), vol. 80, pages 466 - 471
    - SELIGSOHN ET AL., BLOOD, (1978), vol. 52, pages 978 - 988
    - MORISSEY ET AL., BLOOD, (1993), vol. 81, pages 734 - 744
    - CHAVIN; WEIDNER, J. BIOL. CHEM., (1984), vol. 259, pages 3387 - 3390
    - VAN WIJK ET AL., THROMB. RES., (1981), vol. 22, pages 681 - 686
    - COMB ET AL., BLOOD, (1984), vol. 63, pages 15 - 21
    - HEEB ET AL., J. THROMB. HAEMOST., (2006), vol. 4, pages 385 - 391
    - PETROVAN ET AL., AM. J. CLIN. PATHOL., (1999), vol. 112, pages 705 - 711
    - TABATABAI ET AL., THROMB. HAEMOST., (2001), vol. 85, pages 655 - 660
    - BICK ET AL., BEITR. PATHOL., (1973), vol. 150, pages 311 - 315
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.